ArticlebioRxiv : the preprint server for biology2026
Robotic perturbation proteomics and AI agents enable scalable drug mechanism discovery.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Large-scale mass spectrometry-based proteomic screening could reveal cellular mechanisms of drug action at systems resolution but remains limited by experimental complexity and the difficulty of extracting insight from high-dimensional datasets. Here, we describe an end-to-end platform that combines semi-automated sample preparation, rapid LC-MS/MS, and AI agent-based data analysis to enable scalable proteomic screening. In a screen of 172 compounds in HepG2 cells, we generated 1,232 proteomes with more than 8,700 quantified proteins in approximately three weeks. Agentic AI reduced data analysis and interpretation time to less than one day while translating proteomic measurements into structured mechanism-oriented summaries and experimentally testable hypotheses. Guided by this framework, we validated: (1) a cholesterol-lowering effect of methylene blue
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.